Research suggests that Epimedium and its active compound icariin have demonstrated anti-fatigue effects in preclinical settings, with one 2024 animal study showing improved endurance, reduced lactic acid buildup, and activation of energy-regulating pathways in mice, and review literature from 2023 and 2024 noting anti-fatigue activity among the plant's documented pharmacological and traditional uses. However, the only identified human clinical trial, a 2021 randomized controlled crossover study, found no significant reduction in fatigue or symptom severity in participants with Gulf War Illness compared to placebo. The overall evidence base is limited by a heavy reliance on animal and review sources, with the sole human trial failing to replicate the positive signals seen in laboratory settings. Studies indicate that while the preclinical picture is promising, meaningful conclusions about fatigue relief in humans cannot yet be drawn from the available research.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Experimental study on the antifatigue effect of icariin. | Other | 2024 | Supports | 97 |
| A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents ... | RCT | 2021 | — | 82 |
| Research progress on the extraction technology and activity study of Epimediu... | Review | 2023 | Supports | 78 |
| Cancer-Related Therapeutic Potential of Epimedium and Its Extracts. | Review | 2024 | Supports | 65 |